Is linezolid useful against non-tuberculous mycobacteria?

Non-tuberculous mycobacteria (NTM) are a type of mycobacteria that are different from Mycobacterium tuberculosis and can also cause disease in humans. Linezolid has shown certain efficacy in treating these bacterial infections.

Linezolid is a synthetic oxazolidinone antibiotic. Its mechanism of action is to bind to the 50S subunit of bacterial ribosomes, inhibiting the connection between mRNA and ribosomes, thereby preventing the formation of the 70S initiation complex. This mode of action inhibits bacterial protein synthesis at an early stage and therefore has a powerful antibacterial effect.

Linezolid has shown some efficacy in the treatment of non-tuberculous mycobacterial infections. It can not only inhibit the growth of non-tuberculous mycobacteria, but also reduce the number of germs to a certain extent, thereby alleviating the condition. Linezolid has shown good therapeutic effects against some specific non-tuberculous mycobacteria, such as Mycobacterium abscessus and Mycobacterium kansasii.

Of note, linezolid is not effective against all nontuberculous mycobacteria. Different types of non-tuberculous mycobacteria have different susceptibility to drugs, so before treatment with linezolid, it is best to conduct a drug susceptibility test to determine the sensitivity of the bacteria to drugs.

Although linezolid has some efficacy in the treatment of non-tuberculous mycobacterial infections, its use should be contraindicated in patients who are allergic to linezolid. Patients with hepatic and renal insufficiency should use it with caution and adjust the dosage according to the doctor's recommendations. Long-term use of linezolid may lead to the development of drug resistance in bacteria, so you should follow your doctor's guidance when using the drug rationally. During the medication period, you should pay close attention to the side effects and adverse reactions of the medication, such as nausea, headache, diarrhea and vomiting, etc., and report them to the doctor in time.

References:

https://pmc.ncbi.nlm.nih.gov/articles/PMC153345/

xa0